Targeted radio-nuclide therapy of skeletal metastases.

Oliver Sartor, Peter Hoskin, Oyvind S Bruland

Dept. of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA. osartor@tulane.edu

Cancer treatment reviews 2013 Feb

filter terms:

In this review, we will focus on one particular class of stromal targeted therapy, i.e. the bone seeking radiopharmaceuticals (BSRs), but will also highlight selected issues related to the bone stroma as these concepts are new, rapidly evolving, and clearly linked to the underlying BSR mechanisms of targeting and action. Herein we review clinical BSR-trials of significance with randomized trials at center stage. Furthermore, we cover a new class of BSR in late clinical development based on bone-stromal targeted alpha-particle irradiation. Lastly, we discuss potential advances in combining BSR with bisphosphonates and/or chemotherapy and emphasize the feasibility of repeated dosing. Copyright © 2012 Elsevier Ltd. All rights reserved.

Citation

Oliver Sartor, Peter Hoskin, Oyvind S Bruland. Targeted radio-nuclide therapy of skeletal metastases. Cancer treatment reviews. 2013 Feb;39(1):18-26